Menu
Annual · values2025202420232022202120202019201820172016
Gross Margin62.72%-6749.50%-322.63%88.57%60.00%
Operating Margin-5743.53%-85004.58%-670885.82%-92.17%-989.46%
EBITDA Margin-83036.44%-650204.33%-90.59%-984.69%
Net Margin-5570.61%-86888.57%-719859.94%-91.27%-988.49%
Current Ratio2.680.172.176.131.971.834.936.419.578.00
Quick Ratio2.680.172.166.131.971.834.936.419.578.00
Debt / Equity
ROE-110.36%380.41%-302.93%-162.53%-62.44%-129.18%-180.20%-102.24%-100.77%-117.43%
ROA-87.54%-1358.28%-94.72%-90.25%-40.36%-58.31%-143.95%-86.20%-90.90%-102.93%
Asset Turnover0.020.020.000.440.06
Book Value / Share8.21-15.720.220.510.780.73

Hyperion DeFi, Inc. is a public company that integrates decentralized finance (DeFi) strategies with a primary focus on blockchain-based digital assets. Following its rebranding from Eyenovia, Inc. in July 2025, the company shifted from ophthalmic technology to building and managing a strategic treasury centered on the HYPE token, the native asset of the Hyperliquid blockchain protocol. As the first U.S. publicly listed firm to adopt such a DeFi-centric approach, Hyperion DeFi actively accumulates and stakes HYPE tokens through its proprietary and co-branded validators to generate on-chain yield and facilitate blockchain infrastructure. Beyond its treasury operations, Hyperion DeFi pursues partnerships that allow institutional players to access compliant liquid staking solutions and on-chain trading strategies, positioning itself as a bridge between traditional financial systems and emerging DeFi platforms. The company remains notable within the market for enabling shareholder exposure to digital assets and DeFi revenue streams while still maintaining a legacy interest in ophthalmic device innovation. This dual approach highlights Hyperion DeFi’s distinctive role in aligning digital asset management with real-world applications, underscoring its significance as a pioneer in the evolving intersection of traditional markets and blockchain-based finance.